Selection of blockbuster announcements

1、$XIAOMI-W (01810.HK)$Adjusted net profit fell 59.1% to 2.117 billion yuan

XIAOMI Group's third-quarter revenue was 70.47 billion yuan, estimated at 70.16 billion yuan, down 9.7% from the same period last year. XIAOMI Group's adjusted net profit in the third quarter was 2.12 billion yuan, estimated at 1.99 billion yuan, down 59% from the same period last year. Including innovative business expenses such as smart electric vehicles is 829 million yuan. Research and development spending increased by 8.1% from 3.8 billion yuan in the second quarter of 2022 to 4.1 billion yuan in the third quarter of 2022, mainly due to an increase in R & D spending related to innovative businesses such as smart electric vehicles.

Smartphone business revenue in the third quarter was 42.5 billion yuan, up 0.6% from the previous quarter. Global smartphone shipments were 40.2 million units, up 2.8% from the previous quarter. Despite the pressure on the market environment, shipments increased for two consecutive quarters compared with the previous quarter.

2、$CHINA RAILWAY (00390.HK)$Recent major projects have won bids totaling about 86.525 billion yuan

China Rallway announced that recently, the company has won a number of major projects, with a total bid price of about 86.525 billion yuan, accounting for about 8.08% of the company's 2021 operating income under Chinese accounting standards.

3、$CSPC PHARMA (01093.HK)$"SYHX1901 tablet" used in the treatment of severe cases COVID-19 was approved in clinical trial

CSPC Pharmaceutical announced that the "SYHX1901 tablet" developed by the group has been approved by China's State Drug Administration to carry out clinical trials for the treatment of critically ill COVID-19 (COVID-19) adult patients in China.

SYHX1901 tablet is a small molecular compound developed by the Group and is a global innovation drug for Class 1 chemicals in China.

4、$ASCLETIS-B (01672.HK)$COVID-19 's oral drug 3CLpro inhibitor ASC11 new drug clinical trial application is approved by FDA of the United States

Golly Pharmaceutical-B announced that the US Food and Drug Administration (FDA) has approved COVID-19 's application for a new drug clinical trial (IND) for oral candidate drug protease (3CLpro) inhibitor ASC11. FDA approved the safety, tolerance and pharmacokinetics of different doses of ASC11 combined with 100mg ritonavir tablets in healthy volunteers. Both ASC11 and ritonavir tablets are produced by Golly.

5、$TENCENT (00700.HK)$On November 23rd, about HK $352 million was spent to buy back 1.25 million shares.

Tencent announced that the company spent about HK $352 million on November 23, 2022 to buy back 1.25 million shares at a repurchase price of HK $277.8-HK $284.8 per share. On the same day, the company issued 50, 000 shares for its employees exercising options under the share option plan at an issue price of HK $144.7 per share, a discount of 47.84 per cent from the previous business day's closing price of HK $277.4.

Financial data

XIAOMI (01810) Q3 revenue of 70.474 billion yuan, down 9.7% from the same period last year.

Perfect Medical (01830) interim net profit fell 30.4% to HK $151 million interim interest rate of HK13.0 cents

South-South Resources (01229) announced results: interim net loss of HK $241 million

Listing of new shares

The final selling price of 360 DigiTech Inc-S (03660) is determined at HK $50.03 per share.

Investment and operation

China Rallway (00390): the total winning bid for recent major projects is about 86.525 billion yuan.

CSPC Pharmaceutical (01093) "SYHX1901 tablet" for the treatment of severe illness COVID-19 was approved in clinical trial

Golly Pharmaceutical-B (01672): COVID-19 Oral Drug 3CLpro inhibitor ASC11 New Drug Clinical trial Application approved by FDA of the United States

Ganfeng Lithium (01772): planning for spin-off listing of Ganfeng Lithium Power, a holding subsidiary

The board of directors of Weichai Power (02338) has considered and approved the possibility of spinning off the shares of Tsai Leiwo and listing them independently on the growth Enterprise Market of Shenzhen Stock Exchange.

Harbin Electric (01133) spends 500 million yuan to subscribe for 39.4 million shares of Southern Network Energy Storage (600995.SH)

Luoyang Glass Co., Ltd. (01108) plans to acquire the remaining 40% equity of Northern Glass at 164 million yuan and transfer 100% equity of Puyang Optical Materials to Puyang Glass at 327 million yuan.

Rongxin China (03301) and Rongxin property (02207) renew the general agreement on property management and related services.

China General account (03969) won nine important projects in the rail transit market from September to October.

Yidu Science and Technology (02158): won the bid Guangzhou Respiratory Health Research Institute PIONEER Research Technical Service Project

Repurchase cancellation

China Petroleum & Chemical Corporation (00386) spent HK $79.205 million to buy back 22.534 million shares on November 23rd

Tencent (00700) spent HK $352 million to buy back 1.25 million shares on November 23rd

AIA Group Limited (01299) spent HK $225 million to buy back 3.0174 million shares on November 23rd

Swire AG A (00019) spent HK $18.459 million to buy back 309000 shares on November 23rd

Swire AG B (00087) spent HK $4.5795 million to buy back 500000 shares on November 23rd

Great Wall Motor (02333) spent HK $222.7 million to buy back 22.6025 million shares on November 23rd

Sinotrans (00598) spent HK $4.915 million to buy back 2.096 million shares on November 23rd

ESR Cayman Limited (01821) spent HK $7.293 million to buy back 450000 shares on November 23rd

Bailongyun-W (06608) spent HK $4.525 million to buy back 580000 shares on November 23rd

Equity incentive

JD Health (06618) issued an additional 8 million shares under the share incentive scheme

Yunkang Group (02325) adopts 2022 restricted share Unit Plan

Increase and decrease holdings

Jinli permanent Magnet (06680) won Ganzhou Geshuo to reduce 16.7286 million shares. The plan has been completed.

Financing and placing

Beijing Holdings (00392) secured a loan of 170 million euros

Agile Group (03383) completed an old-to-new placement of 295 million shares with a net raise of about HK $783 million.

Change the name of the company

Yuantong Express International (06123) dual foreign name changed to "Yuantong International Express supply chain Technology Co., Ltd."

Luoyang Glass Co., Ltd. (01108) plans to change its name to Kaisheng New Energy Co., Ltd.